Thyrocare Q2FY27 Revenue Up 25.1% to ₹270.8 Cr, PAT Before Exceptions Up 25.7%
Thyrocare Technologies reported Q2FY27 consolidated revenue of ₹270.8 crore, up 25.1% YoY. PAT before exceptional items rose 25.7% YoY to ₹60.2 crore. The company processed 61.6 million tests, a 27.4% YoY increase. An exceptional charge of ₹45 crore relates to the proposed sale of the NHL business. Thyrocare launched a Pregnancy Test Kit.
The significant year-on-year growth in key financial metrics, coupled with strategic initiatives like the divestment of a non-core business to focus on a high-growth segment and the launch of new products, are expected to have a substantial impact on the company's future performance.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT before exceptional items, along with an increase in the number of tests processed. The launch of new products and expansion into specialty diagnostics also contribute positively.
Thyrocare Technologies Limited has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a consolidated revenue of ₹270.8 crore for Q2FY27, marking a 25.1% year-on-year growth. This growth was primarily driven by a 26.7% increase in the Pathology segment.
In the Pathology business, franchise revenue grew by 26.9% year-on-year, while partnership revenue saw a 27.9% year-on-year increase. Thyrocare, as India's largest diagnostic test volume processor, processed 61.6 million tests in Q2FY27, a 27.4% year-on-year increase. Consolidated EBITDA grew by 24.9% year-on-year to ₹89.3 crore, and Profit After Tax (PAT) before exceptional items increased by 25.7% year-on-year to ₹60.2 crore.
An exceptional item of ₹45 crore, a one-time, non-cash impairment charge related to the NHL business in connection with its proposed sale, was recognized in the consolidated books. This charge does not impact the company's operational performance. Thyrocare is seeking shareholders' approval via postal ballot for the divestment of its Nuclear Imaging business to focus on its Pathology segment.
The company maintained its Six Sigma quality standards, reducing complaints per million tests by 24% year-on-year to 2.90, with an Average Turnaround Time (ATAT) of 3.49 hours. Thyrocare has also launched a Pregnancy Test Kit, a rapid home-testing solution, and has onboarded actress Yami Gautam as its brand ambassador. The company is expanding its specialty diagnostics portfolio, starting with allergy and genomics.
What to do with a filing like this
Thyrocare Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Thyrocare Technologies Limited. Read the original for the full detail.